Solid Biosciences (SLDB) Change in Accured Expenses (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Change in Accured Expenses data on file, last reported at -$473000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 72.0% year-over-year to -$473000.0; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 9.96% YoY), and the FY2025 full-year result was $4.0 million, down 15.02% from the prior year.
• Change in Accured Expenses retreated to -$473000.0 in Q1 2026, from $152000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.7 million in Q2 2022 to a low of -$5.0 million in Q3 2022.
• A 5-year average of $424000.0 and a median of $152000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 1515.01% in 2022, while the deepest fall reached 1544.37% in 2022.
• Tracing SLDB's Change in Accured Expenses over 5 years: stood at $2.6 million in 2022, then slumped by 164.03% to -$1.6 million in 2023, then surged by 198.72% to $1.6 million in 2024, then slumped by 90.64% to $152000.0 in 2025, then slumped by 411.18% to -$473000.0 in 2026.
• Business Quant data shows SLDB's Change in Accured Expenses at -$473000.0 in Q1 2026, $152000.0 in Q4 2025, and $2.2 million in Q3 2025.